• Tue news: BioNTech breast cancer treatment promising. Cardiff Onc drug in colorectal cancer. What’s next for 23andMe? UniQure Huntington’s success. GSK in AI collab. See more on our front page

Managed Care Access

anonymous

Guest
If I was an Austedo rep I wouldn’t bother going to work. Us Ingrezza reps are doing all the work for them! I have lost out on so many new starts bc of managed care access. It’s such a shame. Just so Neurocrine could save a few bucks.
 




































Bullshit, we are losing bc of managed care access. Plain and simple. Management can ignore that all they want. But it’s a fact!
They simply can't ignore the fact that as long as Teva is one of the world's largest generic manufactures in Pharma, they will always have the upper hand in negotiating better mc plan coverage. They bundle discounts in with hundreds of their products which allows Austedo to be preferred. The shareholders must be oblivious to this.